Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: A prospective, open-label, parallel-cohort, single-center study

Arthritis and Rheumatism

Volumn 63, Issue 6, 2011, Pages 1486-1496

  Gabay, Cem ^a   Bel, Michael ^a   Combescure, Christophe ^a   Ribi, Camillo ^a   Meier, Sara ^a   Posfay Barbe, Klara ^a   Grillet, Stéphane ^a   Seebach, Jörg D ^a   Kaiser, Laurent ^a   Wunderli, Werner ^a   Guerne, Pierre André ^a   Siegrist, Claire Anne ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AS03; AZATHIOPRINE; CYCLOPHOSPHAMIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; ARTICLE; B LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG TOLERABILITY; FEMALE; HAIR LOSS; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNIZATION; INFLUENZA A (H1N1); INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SPONDYLARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC VASCULITIS;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTIBODIES, VIRAL; ANTIBODY FORMATION; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MALE; MIDDLE AGED; SPONDYLARTHRITIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79958055765     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30325     Document Type: Article

References (50)

1. Gabriel SE, Crowson CS, Maradit Kremers H, Doran MF, Turesson C, O'Fallon WM, et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 2003; 48: 54-8. (Pubitemid 36091647)
2. Symmons DP, Jones MA, Scott DL, Prior P,. Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 1998; 25: 1072-7. (Pubitemid 28350878)
3. Noel V, Lortholary O, Casassus P, Cohen P, Genereau T, Andre MH, et al. Risk factors and prognostic influence of infection in a single cohort of 87 adults with systemic lupus erythematosus. Ann Rheum Dis 2001; 60: 1141-4. (Pubitemid 33096079)
4. Hayden FG,. Prevention and treatment of influenza in immunocompromised patients. Am J Med 1997; 102: 55-60.
5. Nicholson KG, Wood JM, Zambon M,. Influenza. Lancet 2003; 362: 1733-45. (Pubitemid 37468326)
6. Herron A, Dettleff G, Hixon B, Brandwin L, Ortbals D, Hornick R, et al. Influenza vaccination in patients with rheumatic diseases: safety and efficacy. JAMA 1979; 242: 53-6.
7. Williams GW, Steinberg AD, Reinertsen JL, Klassen LW, Decker JL, Dolin R,. Influenza immunization in systemic lupus erythematosus: a double-blind trial. Ann Intern Med 1978; 88: 729-34. (Pubitemid 8351370)
8. Battafarano DF, Battafarano NJ, Larsen L, Dyer PD, Older SA, Muehlbauer S, et al. Antigen-specific antibody responses in lupus patients following immunization. Arthritis Rheum 1998; 41: 1828-34. (Pubitemid 28465537)
9. Abu-Shakra M, Zalmanson S, Neumann L, Flusser D, Sukenik S, Buskila D,. Influenza virus vaccination of patients with systemic lupus erythematosus: effects on disease activity. J Rheumatol 2000; 27: 1681-5. (Pubitemid 30462811)
10. Chalmers A, Scheifele D, Patterson C, Williams D, Weber J, Shuckett R, et al. Immunization of patients with rheumatoid arthritis against influenza: a study of vaccine safety and immunogenicity. J Rheumatol 1994; 21: 1203-6. (Pubitemid 24234652)
11. Del Porto F, Lagana B, Biselli R, Donatelli I, Campitelli L, Nisini R, et al. Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis: safety and immunogenicity. Vaccine 2006; 24: 3217-23.
12. Kaine JL, Kivitz AJ, Birbara C, Luo AY,. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol 2007; 34: 272-9.
13. Stojanovich L,. Influenza vaccination of patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Clin Dev Immunol 2006; 13: 373-5. (Pubitemid 44950054)
14. Kanakoudi-Tsakalidou F, Trachana M, Pratsidou-Gertsi P, Tsitsami E, Kyriazopoulou-Dalaina V,. Influenza vaccination in children with chronic rheumatic diseases and long-term immunosuppressive therapy. Clin Exp Rheumatol 2001; 19: 589-94. (Pubitemid 32894612)
15. Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009; 361: 2424-35.
16. Schwarz TF, Horacek T, Knuf M, Damman HG, Roman F, Drame M, et al. Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine 2009; 27: 6284-90.
17. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24. (Pubitemid 18091653)
18. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al, and the European Spondylarthropathy Study Group. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991; 34: 1218-27.
19. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7. (Pubitemid 13221242)
20. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-92. (Pubitemid 24065492)
21. Ikram H, Prince AM,. A method for coupling cytomegalovirus antigens to aldehyde-fixed erythrocytes for use in passive hemagglutination. J Virol Methods 1983; 7: 127-34. (Pubitemid 13018452)
22. Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, Zambon M,. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet 2010; 375: 1100-8.
23. Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009; 68: 954-60.
24. Stucki G, Liang MH, Stucki S, Bruhlmann P, Michel BA,. A self-administered Rheumatoid Arthritis Disease Activity Index (RADAI) for epidemiologic research: psychometric properties and correlation with parameters of disease activity. Arthritis Rheum 1995; 38: 795-8.
25. Fries JF, Spitz PW, Kraines RG, Holman HR,. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-45. (Pubitemid 10164318)
26. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A,. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 2286-91.
27. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-40.
28. Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 2009; 68: 1827-32.
29. Bernasconi NL, Traggiai E, Lanzavecchia A,. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002; 298: 2199-202. (Pubitemid 35471246)
30. Wraith DC, Goldman M, Lambert PH,. Vaccination and autoimmune disease: what is the evidence? Lancet 2003; 362: 1659-66. (Pubitemid 37443537)
31. Salemi S, D'Amelio R,. Are anti-infectious vaccinations safe and effective in patients with autoimmunity? Int Rev Immunol 2010; 29: 270-314.
32. Rahier JF, Moutschen M, van Gompel A, van Ranst M, Louis E, Segaert S, et al. Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology (Oxford) 2010; 49: 1815-27.
33. Abu-Shakra M, Press J, Varsano N, Levy V, Mendelson E, Sukenik S, et al. Specific antibody response after influenza immunization in systemic lupus erythematosus. J Rheumatol 2002; 29: 2555-7. (Pubitemid 35416961)
34. Holvast A, Huckriede A, Wilschut J, Horst G, de Vries JJ, Benne CA, et al. Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann Rheum Dis 2006; 65: 913-8.
35. Fomin I, Caspi D, Levy V, Varsano N, Shalev Y, Paran D, et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNFα blockers. Ann Rheum Dis 2006; 65: 191-4. (Pubitemid 43131992)
36. Kapetanovic MC, Saxne T, Nilsson JA, Geborek P,. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology (Oxford) 2007; 46: 608-11. (Pubitemid 46523304)
37. Wallin L, Quintilio W, Locatelli F, Cassel A, Silva MB, Skare TL,. Safety and efficiency of influenza vaccination in systemic lupus erythematosus patients. Acta Reumatol Port 2009; 34: 498-502.
38. Elkayam O, Bashkin A, Mandelboim M, Litinsky I, Comaheshter D, Levartovsky D, et al. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 2010; 39: 442-7.
39. Van Assen S, Holvast A, Benne CA, Posthumus MD, van Leeuwen MA, Voskuyl AE, et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010; 62: 75-81.
40. Kubota T, Nii T, Nanki T, Kohsaka H, Harigai M, Komano Y, et al. Anti-tumor necrosis factor therapy does not diminish the immune response to influenza vaccine in Japanese patients with rheumatoid arthritis. Mod Rheumatol 2007; 17: 531-3.
41. Gelinck LB, van der Bijl AE, Beyer WE, Visser LG, Huizinga TW, van Hogezand RA, et al. The effect of anti-tumour necrosis factor α treatment on the antibody response to influenza vaccination. Ann Rheum Dis 2008; 67: 713-6. (Pubitemid 351571939)
42. Oren S, Mandelboim M, Braun-Moscovici Y, Paran D, Ablin J, Litinsky I, et al. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis 2008; 67: 937-41. (Pubitemid 351956654)
43. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC,. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 613-20. (Pubitemid 43228639)
44. Roman F, Vaman T, Kafeja F, Hanon E, van Damme P,. AS03(A)-adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. Clin Infect Dis 2010; 51: 668-77.
45. Gross PA, Sperber SJ, Donabedian A, Dran S, Morchel G, Cataruozolo P, et al. Paradoxical response to a novel influenza virus vaccine strain: the effect of prior immunization. Vaccine 1999; 17: 2284-9. (Pubitemid 29225680)
46. Holvast A, Stegeman CA, Benne CA, Huckriede A, Wilschut JC, Palache AM, et al. Wegener's granulomatosis patients show an adequate antibody response to influenza vaccination. Ann Rheum Dis 2009; 68: 873-8.
47. Davenport FM, Hennessy AV, Francis T Jr., Epidemiologic and immunologic significance of age distribution of antibody to antigenic variants of influenza virus. J Exp Med 1953; 98: 641-56.
48. Holvast A, van Assen S, de Haan A, Huckriede A, Benne CA, Westra J, et al. Effect of a second, booster, influenza vaccination on antibody responses in quiescent systemic lupus erythematosus: an open, prospective, controlled study. Rheumatology (Oxford) 2009; 48: 1294-9.
49. Salemi S, Picchianti-Diamanti A, Germano V, Donatelli I, di Martino A, Facchini M, et al. Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFα blockers: safety and immunogenicity. Clin Immunol 2010; 134: 113-20.
50. Prymula R, Siegrist CA, Chlibek R, Zemlickova H, Vackova M, Smetana J, et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. Lancet 2009; 374: 1339-50.